The discovery of two new p53 homologs, p73 and p63, has defined a family of transcription factors heavily involved in the control of growth suppression, apoptosis, differentiation and development. While p53-deficient mice undergo spontaneous tumors, p73 and p63 knockout mice exhibit severe developmental defects. We demonstrate here that p73 gene is an in vivo transcriptional target of the muscle regulatory factors MyoD, myogenin, Myf5 and Myf6. Ectopic expression of the transcriptional repressor dEF1/ZEB/zfhx1a counteracts MyoD/Myf5-or MyoD/Myf6-mediated transcriptional activation of p73. A distinct pattern of in vivo recruitment of muscle regulatory factors and dEF1 on p73 regulatory regions was found between proliferating and differentiating muscle cells. We also found that dEF1 plays a role in the transcriptional regulation of p53 family members during keratinocytic differentiation. Mouse embryo fibroblasts derived from dEF1-deficient mice exhibit unbalanced expression of DNp63, TAp73 and DNp73 but not of TAp63 and p53. The analysis of tissues derived from dEF1 þ /À mice exhibit a selective enrichment of DNp63 in skin.
Introduction
The recently discovered p53 family comprises 20 proteins whose main activities are closely related to growth arrest, apoptosis, differentiation and development. The most recently identified p53 family members, p73 and p63, depict a quite similar modular structure compared to that of p53 (Jost et al., 1997; Kaghad et al., 1997; Blandino and Dobbelstein, 2004 ). The C-ter of p73 and p63 is subjected to alternative splicing giving rise to a family of different isoforms (Kaghad et al., 1997 , De Laurenzi et al., 1998 . N-terminal-truncated isoforms (DN) of p73 and p63 that take origin from a cryptic promoter located in the third intron of the genes are also present in living cells. Ectopic expression of p73 and p63 in p53 þ / þ and p53À/À cancer cells induces growth arrest, apoptosis and differentiation recapitulating some of the p53 biological activities (Kaghad et al., 1997; Jost et al., 1997) . Despite it, the phenotypes of p73 and p63 knockout mice exhibit severe defects, respectively, in neuronal and epithelial development (Mills et al., 1999; Yang et al., 1999 Yang et al., , 2000 .
It has become increasingly clear that regulation of gene expression is driven by the differential activity of transcriptional regulators whose cell and tissue distribution is often wider than their target genes. It has been reported that p73 expression is triggered along neuronal, hematopoietic, and muscle differentiation (Fontemaggi et al., 2001; Morena et al., 2002; Blandino and Dobbelstein, 2004) , although evidences responsible for this modulation are still needed. We have originally shown that the negative regulator dEF1 binds in proliferating cells to the first intron of p73 through E-box-like (CACCT and CACCTG) sequences. This binding was clearly reduced during differentiation of C2C12 cells. dEF1 has recently been identified as the vertebrate homolog of the Drosophila zinc-finger homeodomain factor, zfh-1 (Fortini et al., 1991; Genetta et al., 1994) . Zfh proteins are required for proper differentiation of the central nervous system and for the early process of organogenesis in mesodermal tissues (Lundell and Hirsh, 1992; Lai et al., 1993) . Zfh-1 mutants show imbalanced distribution as well as defects in the segregation of muscle precursors (Postigo and Dean, 1997) . dEF1-null mutant mice develop to term but never survived postnatally; they exhibit severe skeletal defects of various lineages and defects in hematopoiesis (Higashi et al., 1997; Takagi et al., 1998) .
Here, we show that muscle regulatory factors (MRFs) function as transcriptional activators of p73. Ectopic expression of dEF1 counteracts MyoD/Myf5-mediated transcriptional activation of p73. A distinct pattern of in vivo recruitment of MRFs and dEF1 on p73 regulatory regions was found between proliferating and differentiating muscle cells. dEF1-null mouse embryo fibroblasts (MEFs) show restored expression of TAp73/DNp73 and DNp63, but not of TAp63 and p53. DNp63 expression is also increased in dEF1 þ /À skin, the tissue in which it has been reported to play a major role. Moreover dEF1 controls transcriptionally DNp63 during keratinocytic differentiation, indicating an involvement of dEF1 in the control of expression of specific p53 family members during differentiation.
Results

MRFs are transcriptional activators of p73
We have previously shown that dEF1 functions as a transcriptional repressor of p73 through the binding to six consensus sites located in the first intron of p73 gene (Fontemaggi et al., 2001) . The six consensus included three CACCT and three CACCTG (E-box) sequences. Sequence analysis of p73 gene revealed that the promoter region also includes a cluster of 14 dEF1 consensus sequences, 10 of which are CACCTG Eboxes. Since E-box sequences were also shown to be binding sites for MRFs, such as MyoD, Myogenin, Myf5 and Myf6, we aimed to assess whether p73 is a transcriptional target of MRFs.
To this end, we employed transactivation assays to measure the transcriptional activity of Myf5, Myf6, MyoD on p73 regulatory regions. We used two different reporter constructs, called p73P1 and p73intr1, containing respectively, 4 kb of the promoter and 1 kb of the first intron in front of the luciferase reporter gene. We found that MyoD, at least under our experimental conditions, was a weak transcriptional activator of p73 (Figure 1a and b) . Ectopic expression of Myf5 or Myf6 did not promote any transcriptional activation of p73 regulatory regions (Figure 1a and b) . Of note, the concomitant expression of MyoD and Myf5 or Myf6 strongly activated p73 regulatory regions, indicating a synergistic effect of MRFs in the transcriptional activation of p73 (Figure 1a and b) . The latter was not observed either on a shorter p73 promoter that lacks Ebox sequences (Dp73P1) or on the intronic fragment of p73 contaning six consensus mutated (M6p73intr1). The specificity of the transactivation was also confirmed by the result that p53 promoter, which does not contain any E-box, is not activated by the combination of MyoD and Myf5 (Figure 1a) . Altogether, the reported results indicate that p73 promoter and first intron are responsive to the transactivation mediated by MRFs.
MRFs bind in vivo to p73 regulatory regions
Since it has been shown that dEF1 and MRFs can compete for their consensus sequences on some target genes during muscle differentiation (Postigo and Dean, 1997), we were interested in investigating whether it occurs also for p73. To analyse the binding pattern of dEF1 and MRFs on p73 regulatory regions during muscle differentiation, we performed chromatin immunoprecipitation (ChIP) analysis on C2C12 cells. As shown in Figure 2a and b, dEF1 binds to both the promoter and intron 1 of p73 in proliferating cells. This binding markedly diminishes during differentiation and is restored when cells are terminally differentiated. Conversely, MRFs bind to p73 regulatory regions mainly during the differentiation (Figure 2a and b) .
Moreover, we found that the degree of histone H4 acetylation on p73 regulatory regions is enhanced during the differentiation (Figure 2a and b, lower panels). This correlates with the binding of MRF on p73 regulatory regions and with the kinetics of p73 mRNA expression (Figure 2d ) during muscle differentiation.
To confirm in vitro the displacement model between dEF1 and MyoD, we performed an electrophoretic mobility shift assay. As shown in Figure 2c (upper and middle panels), in vitro translated dEF1 and MyoD proteins are able to bind specifically to CACCTG box present in the p73 first intron. Increasing amounts of MyoD protein displace the binding of dEF1 to its consensus sequence (Figure 2c , lower panel).
Next, we wanted to analyse whether dEF1 and MRFs were able to compete for their target sequences in transactivation assays. To verify whether dEF1 could counteract the transcriptional activation of p73 regulatory regions exerted by MRFs, we performed transactivation assays using increasing amounts of ectopically expressed dEF1. As shown in Figure 2e and f, we found that dEF1 strongly reduced, in a dose-dependent manner, MyoD/Myf5-mediated activation of p73 regulatory regions. Altogether, these results suggest the existence of an in vivo crosstalk between muscle transcription factors and the transcriptional repressor dEF1 in the control of p73 expression during muscle differentiation.
dEF1 drives selectively the expression of specific p53 family members
To investigate the potential involvement of dEF1 on the transcriptional control of other p53 family members, we analysed through RT-PCR assays the transcripts of p53 family members in either MEFs obtained from dEF1-null, heterozygous and wild-type embryos or MEFs transfected with a dEF1 dominant negative (DB-ZEB). We found (Figure 3a ) that both the TAp73 and DNp73 mRNA levels were increased in dEF1À/À cells, compared to those of the wild-type counterparts. Notably, DNp63 expression was strongly increased in knockout MEFs. Both unbalanced expressions of DNp73 and DNp63 were independent from the lack of one ( þ /À) or two (À/À) alleles of dEF1 (Figure 3a ). The expression of TAp63 and p53 was unaffected (Figure 3a) . These modifications were also found in MEFs overexpressing dominant negative dEF1 (DB-ZEB) (Figure 3b ). The deregulation of the expression of p53 family members was also found at the protein levels as shown in Figure 3c . Since the most evident effect in dEF1 þ /À and À/À cells was observed on DNp63, we assessed its protein expression in skin lysates derived from dEF1 þ /À and þ / þ adult mice. As shown in Figure 4a (upper panel), DNp63 protein was only detectable in dEF1 þ /À skin. On the contrary, this effect was not seen in total brain To verify whether dEF1 exerts transcription on the promoter of DNp63, a fragment (3000 bp) of p63P2 promoter was cloned into pGL3 basic luciferase reporter construct and the transcriptional activities of dEF1 and a dominant negative protein of dEF1 (ZEB-DB) on this promoter fragment were evaluated. We found that DNp63 promoter activity was reduced upon cotransfection of dEF1 expression vector (Figure 4b, left panel) . Furthermore, the exogenous expression of ZEB-DB was able to rescue the transcriptional repression on the p63P2 promoter exerted by endogenous dEF1 protein.
Altogether these results demonstrate that dEF1 repressor regulates at the transcriptional level specific p53 family members, in particular TAp73/DNp73 and DNp63. dEF1 transcriptionally regulates p53 family members during keratinocytic differentiation It has been reported that keratinocyte differentiation is characterized by DNp63 downregulation and p73 upregulation (De Laurenzi et al., 2000; Bamberger et al., 2002) . In agreement with that we found a decrease of DNp63 and an increase of p73b during keratinocyte differentiation of HaCaT cells (Figure 5a ). We aimed to investigate whether this opposite behavior of DNp63 and p73b was regulated at the transcriptional level by dEF1. By computer-assisted analysis we found that p63P2 promoter (the one that drives DNp63 transcription) has two regions containing dEF1 consensus clusters.
Crosslinked chromatin derived from proliferating (P) and terminally differentiated (TD) HaCaT cells was immunoprecipitated with antibodies directed against dEF1 and Myf6 (negative control). As shown in Figure  5b and c, dEF1 was bound to both p63P2 regions. Of note, the amount of bound dEF1 is higher in TD cells, compared to that of proliferating cells. No differences of dEF1 binding were observed on p63P1 (the promoter of TAp63), despite the presence of one consensus (located at À1273 from exon 1). The lack of this effect may be related to the minor changes of TAp63 expression during keratinocyte differentiation (Bamberger et al., 2002) . Conversely, dEF1 binds preferentially p73 promoter in proliferating cells (Figure 5b and c) .
These findings identified dEF1 as a transcriptional regulator of specific p53 family members during keratinocyte differentiation.
Discussion
Differentiation is a tightly regulated process that mainly occurs through the coordinated activation or repression of selected groups of genes. The crossroad between proliferation and differentiation represents certainly a critical step in which the coordinated action of transcriptional activators and repressors needs to be highly integrated to step down proliferation and start the differentiation program. The p53 homologs, p73 and p63, have been turned out to be critical transcription factors in development as clearly shown by the phenotypes of the respective knockout mice (Mills et al., 1999; Yang et al., 1999 Yang et al., , 2000 . Here, we identify the transcriptional repressor dEF1 as a selective regulator of p73, p63, their C-ter-alternative-spliced isoforms and N-ter-truncated proteins during differentiation. Muscle differentiation is mainly driven by the coordinated activity of MRFs. Our findings clearly and originally show that p73 gene is an in vivo transcriptional target of MRFs. While MyoD alone is a weak transcriptional activator of p73, the concomitant expression of either Myf5 or Myf6 results in a further activation of p73 regulatory regions. The critical role that both Myf5 and Myf6 might play in the transcriptional regulation of p73 gene at the crossroad between proliferation and differentiation of muscle cells is also shown by their restricted pattern of in vivo occupancy onto p73 first intron. The latter has been previously shown to exert an important role on the transcriptional regulation of the p73 gene (Fontemaggi et al., 2001) .
Notably, dEF1 repressor is capable to counteract MRFs-mediated transcriptional activation of p73 and its in vivo occupancy between proliferation and differentiation, at least, onto the first intron of p73 is almost opposite to that of MRFs. Altogether, these data provide evidence for the existence of a coordinated network of transcriptional activators -MRFs -and repressor -dEF1 -controlling p73 gene expression during muscle differentiation. dEF1 is widely expressed suggesting that it might serve as a broad transcriptional repressor whose activity is independent from the cell context. Our findings showing that dEF1 controls the expression of p53 family members during keratinocytic differentiation strongly supports this hypothesis.
DNp63 role has been extensively characterized in skin. It has been shown that high DNp63 levels are present in epithelial cells, especially in stem-cell populations of epithelial tissues, where this protein is crucial for the maintenance of proliferative capacity. As these cells start to differentiate, their DNp63 levels gradually drop. Cells that no longer express DNp63 lose the proliferative capacity and are committed to differentiation (Yang and McKeon, 2002) . We found that dEF1 tightly regulates DNp63 expression. Indeed, dEF1 occupies the regulatory regions driving the expression of DNp63 preferentially during keratinocytic differentiation. This pattern of occupancy is opposite to that observed onto p73 regulatory regions, during muscle and keratinocytic differentiation, where dEF1 is preferentially recruited in proliferating cells. Taken together, these data with those showing that reduction of dEF1 repressor activity unbalances DNp63 expression identify dEF1 as a critical transcriptional regulator of the keratinocytic differentiation program. Despite a certain degree of overlapping functions, p73, p63 and their related isoforms perform different activities compared to those of wild-type p53. This could be explained through two different scenarios. The first one is based on the assumption that common transcriptional regulators, interactors, target genes modulate differently the activities of all p53 family members. The second relies on the existence of specific factors regulating, at different levels, the effects of p73 and p63 but not those of p53. We found that dEF1 is a selective transcriptional repressor of p53 family members. While the expression of DNp63, TAp73 and DNp73 is regulated by dEF1, that of p53 is unaffected. These findings highlight dEF1 as a transcriptional regulator that confers specificity to the pathways activated by p73 and p63 family members.
Materials and methods
Cell cultures
C2C12 myoblasts were cultured in DMEM containing 10% fetal bovine serum (FBS); differentiation was induced by plating the cells onto collagen-coated dishes and switching them to serum-free (SF) medium for 72 h: DMEM supplemented with 5 mg/ml human insulin, 5 mg/ml human (holo) transferrin and 5 ng/ml sodium selenite. Ara-C (50 mM) was added to the SF medium to eliminate undifferentiated cells. More than 90% of the cells become terminally differentiated under these conditions, as assessed by MHC (myosin heavy chain) staining. Transformed keratinocyte HaCaT cells and NIH-3T3 cells were cultured in DMEM with 10% FBS. To induce keratinocyte differentiation, confluent HaCaT cells were cultured in 2 mM CaCl 2 serum-free DMEM for 72 h. MEF cells were prepared from dEF1 þ / þ , þ /À and À/À embryos at 13.5 day of gestation and cultured in DMEM with 20% FBS.
Plasmids p73P1-LUC and p73intr1-LUC were described in Fontemaggi et al. (2001) . Dp73P1-LUC was obtained by digestion of the 4 kb promoter contained in p73P1-LUC with StuI, resulting in a 2.6 kb promoter. p63P2-luc was generated by cloning a 3182 bp fragment of DNp63 promoter into SmaI site of pGL3basic vector; the promoter fragment was obtained by PCR using the following oligonucleotides: sense 5 0 -TGACA TCTTGGACTTCTATTCCC-3 0 , antisense 5 0 -CTGTAAGATT GATCAATGCTGCTG-3 0 . pZEB-DB was kindly provided by D Dean, MyoD vector by M Crescenzi, Myf5 and Myf6 vectors by M Grossi and p53 promoter by M Oren.
Site-directed mutagenesis
Site-directed mutagenesis was performed on p73intr1-LUC vector using QuikChanget Site-Directed Mutagenesis kit (Stratagene) according to the manufacturer's protocol. Six consensus for dEF1 were mutated generating M6p73intr1-LUC vector. Oligonucleotide sequences used for mutagenesis are available upon request.
Transfections and luciferase assays
Transient and stable transfections were performed as described in Fontemaggi et al. (2001) .
RNA extraction and RT-PCR analysis
RT/PCR assays were performed as described (Fontemaggi et al., 2001) . Primer sequences used for amplification of murine TAp73, DNp73, TAp63, DNp63, p53, myogenin and human p73b isoform are available upon request.
Western blot analysis
For human and murine p73 detection, the following antibodies were used, respectively: a monoclonal antibody from Neomarker (Ab4); a rabbit polyclonal from Santa Cruz Biotechnology (H79). For human and murine p63 detection, 4A4 monoclonal antibody from Santa Cruz Biotechnology, Inc. was used. For p53 detection, DO1 antibody was used. For ZEB-DB detection, a monoclonal anti-flag (Sigma) antibody was used. For Hsp70 detection, a monoclonal antibody from StressGen was used.
EMSA
EMSAs were performed in a 25 ml DNA-binding reaction that contained 4 fmol of labeled duplex oligonucleotide, binding buffer (20 mM Tris-HCl pH 7.8, 60 mM KCl, 0.5 mM EDTA, 0.1 mM DTT, 3 mM MgCl 2 ), 1.5 mg of poly (dI-dC), 10 mM spermidine and 100-400 ng of salmon sperm and in vitro translated proteins. The reaction was carried out at room temperature for 15 min and the protein-DNA complexes were subjected to native electrophoresis on 5% polyacrylamide, 0.5 Â TBE gels. The following oligonucleotide was used as probe (consensus site is underlined): box6, 5 0 -CCA GGG TGC TCA GGT GTC ATT CCT TCC. In supershift experiments, antibodies were added to the mixture before the labeled oligonucleotide and incubated for 10 min at RT. For supershift of dEF1 and MyoD, the following amounts of antibodies were used, respectively: 5 ml of crude rabbit polyclonal anti-dEF1, 2 mg of affinity-purified polyclonal anti-MyoD (sc-760 from Santa Cruz Biotechnology). The recombinant dEF1 and MyoD proteins used in gel shift assay were produced using TnT Transcription/Translation Coupled Reticulocyte Lysate Systems (Promega) according to the manufacturer's protocol.
Formaldehyde crosslinking and chromatin immunoprecipitation
Formaldehyde crosslinking and ChIP were performed as previously described (Fontemaggi et al., 2001) . The chromatin solution was immunoprecipitated with 10 ml of rabbit polyclonal anti-dEF1 serum, 2 mg of affinity-purified polyclonal antibodies from Santa Cruz Biotechnology, Inc. (myogenin sc-576, MyoD sc-760, Myf5 sc-302, Myf6 sc-784), 2 mg of antiacetyl-histone H4 (cat. n. 06-866, Upstate Biotechnology, Inc.) or no antibody as negative control. For p73 promoter detection, primers that amplify a region from À2736 to À3057 (from exon 1) were used. For p73 intron 1 detection, primers that amplify the 1 kb silencer previously characterized (Fontemaggi et al., 2001) were used. For the promoter of DNp63 (p63P2) two regions, located, respectively, at À1830/ À2260 and À8200/À8492 from translation initiation, were amplified. Primers are available upon request. For ChIP quantization (Figure 4) , the amount of p63P2, p63P1 or p73P1 PCR products present in input samples and in samples immunoprecipitated with anti-dEF1 or with no antibody was measured by densitometry from two experiments, and the media was calculated. For each chromatin, the value of noantibody sample was subtracted from that of anti-dEF1, as a nonspecific binding background, to obtain a corrected value. This corrected value was normalized (as percentage) on the corresponding input sample to obtain Relative Enrichment. Bars represent standard errors.
Real-time PCR analysis
Applied Biosystems 7500 system SDS software was used for real-time PCR analysis of ChIP experiments. The analysis was performed by using SYBR Green DNA Master mix (Applied Biosystems). Absolute quantification was performed using serial dilutions of the input DNA samples to obtain standard curves. The values of negative controls (no antibody) were subtracted from the corresponding samples. Oligonucleotide sequences used for real-time PCR are available upon request.
